BC Innovations | Sep 26, 2018
Distillery Therapeutics

Neurology

INDICATION: Leukodystrophy Cell culture, worm and mouse studies suggest inhibiting HDAC6 and other HDACs could help treat Cockayne syndrome, a leukodystrophy caused by ERCC6 mutations that is associated with defects in autophagy, neurogenesis and neuronal...
BC Week In Review | Aug 10, 2018
Clinical News

FDA approves Kyowa's Poteligeo for CTCL

FDA approved Poteligeo mogamulizumab-kpkc from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) to treat the two most common forms of cutaneous T cell lymphoma (CTCL). The agency approved Poteligeo to treat adults with relapsed or refractory...
BC Innovations | Aug 8, 2018
Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) In vitro , cell culture and mouse studies identified a piperazine-based dual MDM2/HDAC6 inhibitor that could help treat NSCLC. Chemical synthesis and in vitro testing of conjugates consisting of analogs...
BC Extra | Aug 8, 2018
Company News

FDA approves Kyowa's Poteligeo for CTCL

FDA approved Poteligeo mogamulizumab-kpkc from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) to treat the two most common forms of cutaneous T cell lymphoma. The agency approved Poteligeo to treat adults with relapsed or refractory mycosis...
BC Innovations | Jul 10, 2018
Distillery Therapeutics

Otologic

INDICATION: Hereditary deafness Patient samples and mouse studies suggest that inhibiting REST or HDAC could help treat hearing loss associated with gain-of-function REST mutations. In a family with inherited progressive hearing loss, sequencing of a...
BC Extra | Jun 29, 2018
Preclinical News

Inhibiting REST in hair cells to reduce hearing loss

In a Cell paper , a University of Iowa and NIH team showed that an inactive form of RE1-silencing transcription factor (REST; NRSF) is necessary for hearing and suggested that inhibiting REST in hair cells with...
BC Week In Review | Dec 15, 2017
Clinical News

Kyowa's Poteligeo meets in Phase III for CTCL

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) said Poteligeo mogamulizumab (AMG 761, KW-0761) met the primary endpoint of improving progression-free survival (PFS) in the Phase III MAVORIC trial to treat mycosis fungoides or Sézary syndrome, which...
BC Extra | Dec 10, 2017
Clinical News

Kyowa's Poteligeo meets in Phase III for CTCL

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) said Poteligeo mogamulizumab (AMG 761, KW-0761) met the primary endpoint of improving progression-free survival (PFS) in the Phase III MAVORIC trial to treat mycosis fungoides or Sézary syndrome, which...
BC Innovations | Sep 20, 2017
Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer In vitro, cell-based and mouse studies identified an aminoanilide-based dual NamPRT / HDAC1 inhibitor that could help treat colorectal cancer. Chemical synthesis and in vitro testing of ortho -aminoanilide analogs in enzymatic...
BC Innovations | Jul 31, 2017
Distillery Therapeutics

Transplant

INDICATION: Graft-versus-host disease (GvHD) Mouse studies suggest promoting INDO expression with HDAC inhibitors could help treat idiopathic pneumonia syndrome (IPS) associated with hematopoietic stem cell transplant (HSCT). In a mouse model of HSCT-associated IPS, the...
Items per page:
1 - 10 of 146